XFOR X4 Pharmaceuticals Inc

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the 36th Annual Piper Sandler Healthcare Conference, taking place in New York, NY on December 3-5, 2024.

36th Annual Piper Sandler Healthcare Conference

Date:Tuesday, December 3, 2024
Time:11:00AM ET
Format:Fireside Chat
Location:Lotte New York Palace, New York
 
 

This live webcast will also be accessible through “” page of the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a replay of this webcast will be available through the same link.

The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Piper Sandler representative to request meetings.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .

Company Contact:

José Juves

Head of Corporate & Patient Affairs

Investor Contact:

Daniel Ferry

Managing Director, LifeSci Advisors



(617) 430-7576



EN
26/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on X4 Pharmaceuticals Inc

 PRESS RELEASE

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial...

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G-CSF while maintaining ANC levels in the normal range Data continue to strengthen confidence in potential success of ongoing global, pivotal Phase 3 trial evaluating ...

 PRESS RELEASE

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for ...

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain pr...

 PRESS RELEASE

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards c...

 PRESS RELEASE

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic ...

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstra...

 PRESS RELEASE

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Pr...

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates 4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch